Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.
byBenzinga Newsdesk
July 21, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

LianBio Announces China National Medical Products Administration Acceptance With Priority Review Of New Drug Application For Mavacamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy

By Happy Mohamed
April 21, 8:06 AM
LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that China's National Medical Products Administration

LIAN